Challenges in bone reconstruction: beyond autografts

The management of critical bone defects, resulting from trauma, tumor resections, or infections, imposes heavy clinical and economic constraints. Although autograft remains the gold standard, its documented complications — donor site morbidity, limited harvestable volume, and prolonged operative time — necessitate the development of high-performance biomimetic substitutes. Mineralized collagen (MC), combining type I collagen and nanocrystalline hydroxyapatite, faithfully reproduces the bone extracellular matrix, but its function is often limited to that of a passive scaffold lacking intrinsic osteoinductive capacity.

At the same time, Platelet-Rich Plasma (PRP) offers a massive concentration of growth factors (VEGF, PDGF, TGF-β1, IGF-1), but its gel-like consistency lacks the structural stability to maintain space within critical-sized defects. This experimental study evaluates a combined strategy: the impregnation of MC matrices with PRP to create a composite that is both osteoinductive and structurally stable.

The objective is to quantify the impact of this synergy on the proliferation and osteogenic differentiation of mesenchymal stem cells (BMSC) in vitro, as well as on the healing of critical femoral defects (3 mm in diameter) in rats. The authors test the hypothesis that a PRP+MC composite activates the RUNX2 signaling pathway more significantly than the isolated components, promoting accelerated bone regeneration and optimal integration with the host bone.

Experimental approach: synergy between biomimetic matrix and growth factors

This preclinical study adopts a dual methodology, combining in vitro tests on mesenchymal stem cells (rBMSCs) derived from three-week-old Sprague-Dawley rats and an in vivo healing model. The structural support used is a mineralized collagen (MC) scaffold composed of type I collagen and nano-hydroxyapatite, whose porosity (70-80%) and pore size (200-400 µm) mimic the native bone matrix.

The protocol evaluated four experimental arms to isolate the effect of each component:

• PRP + MC: Collagen scaffolds immersed in activated platelet-rich plasma.
• MC: Collagen scaffold alone (BonGold™).
• PRP: Platelet-rich plasma alone, in gel form.
• Control: Application of a physiological saline solution.

PRP was prepared using a double centrifugation protocol from whole blood. For the in vivo component, critical-sized cylindrical defects (3 mm diameter, 5 mm depth) were created in the femoral condyle of male rats. Bone regeneration was analyzed at 12 weeks using micro-computed tomography (Micro-CT) to evaluate trabecular architecture. The quality of the neoformed tissue was characterized by histology (H&E and Masson's trichrome staining) and by the expression level of osteopontin (OPN) via immunohistochemistry to confirm the maturation of lamellar tissue.

Results: A demonstrated biological and structural synergy

The evaluation of the PRP + Mineralized Collagen (MC) combination reveals a statistically significant superiority compared to the components used in isolation, both in terms of cell kinetics and in vivo tissue regeneration.

In vitro cellular performance

Tests conducted on bone marrow mesenchymal stem cells (rBMSC) show that the PRP + MC composite optimizes the differentiation environment:

• Proliferation: A significant increase in rBMSC proliferation was observed on day 7 in the PRP + MC group.
• Osteogenic differentiation: Alkaline phosphatase (ALP) activity and mineralization (evidenced by Alizarin Red S) are marked by a notable increase.
• Gene expression: Analysis by qRT-PCR indicates an upregulation of the RUNX2 gene, with an expression approximately 5.6 times higher than that of the control group.

Bone regeneration in vivo (12 weeks)

Implantation into critical femoral condyle defects in rats (3 mm diameter, 5 mm depth) allowed for the quantification of the composite's efficacy through micro-CT and histomorphometric analysis.

Histological and immunohistochemical analysis

Masson's trichrome and H&E stained sections confirm the perfect integration of the composite into the host bone. The PRP + MC group shows the highest expression of osteopontin (OPN), a key marker of bone maturation. Unlike the control groups where the defect remains filled with fibrous tissue, the composite group displays a smooth transition between the newly formed bone and the defect margins, validating the osteoinductive potential of the combination.

Biological and structural synergy: the benefits of the PRP-Mineralised Collagen composite

This study demonstrates that the association of PRP and mineralized collagen (MC) overcomes the intrinsic limitations of each material used in isolation. Where MC alone acts as a simple passive scaffold and PRP as a concentrate of growth factors without mechanical stability, their combination creates a complete biomimetic substitute. The results are clinically significant: a 5.6-fold increase in RUNX2 expression and a bone regeneration rate reaching 75% at 12 weeks, transforming a critical defect into mature lamellar bone tissue.

For the practitioner, the benefit lies in resolving the issue of PRP instability. By integrating it into a collagen and nanocrystalline hydroxyapatite (MC) matrix, the release of growth factors (VEGF, PDGF, TGF-β1) is stabilized directly at the heart of the surgical site. This approach offers a serious alternative to autografts, without the morbidities associated with the donor site, while demonstrating superior performance to bone morphogenetic proteins (BMP) whose clinical efficacy remains debated in the cited literature.

The study's limitations primarily relate to its preclinical model (SD rat) and a follow-up period limited to 12 weeks. While the proof of concept is solid, transposition to humans, where defect volumes are larger and vascularization is more complex, remains to be validated through clinical trials. Nevertheless, the reproducibility of PRP preparation and the use of a commercial scaffold (BonGold™) facilitate potential adoption in daily practice.

Study summary

This experimental study demonstrates that the PRP + Mineralized Collagen (MC) composite increases RUNX2 expression by 5.6 times and generates approximately 75% of newly formed bone surface within 12 weeks in critical defects. The integration of mature lamellar bone is significantly superior to the MC alone or PRP alone groups, confirming a synergy between the biomimetic structure and biological stimulation.

In concrete terms, for the practitioner:

• Stabilize PRP: use mineralized collagen as a structural scaffold to compensate for the low mechanical stability of PRP alone, thus preventing its displacement or loss in large defects.
• Activate your grafts: transform a passive substitute into an active osteoinductive material; immersing the BM in PRP allows for the local delivery of a cocktail of growth factors (VEGF, PDGF, TGF-β1) that accelerates stem cell differentiation.
• Alternative to autograft: prioritize this biomimetic approach to reduce morbidity related to donor sites, while benefiting from a matrix (type I collagen and nano-hydroxyapatite) chemically identical to native bone.

Technical lexicon of the study

Mineralized Collagen (MC): Biomimetic material composed of type I collagen and nano-crystalline hydroxyapatite (HA). It reproduces the chemical structure and microstructure of the natural bone matrix to serve as a scaffold for regeneration.

Platelet-Rich Plasma (PRP): Autologous plasma concentrate forming a fibrin matrix rich in growth factors (VEGF, PDGF, TGF-β1, IGF-1). It is used for its osteoinductive potential despite low structural integrity when used as a gel alone.

RUNX2: Key transcription factor for osteoblastic differentiation. The study shows that its mRNA expression is up-regulated (approximately 5.6-fold compared to control) under the influence of the PRP + MC composite.

Critical size defect: Experimental model of bone lesion (here 3 mm in diameter and 5 mm in depth in the rat femoral condyle) that cannot heal spontaneously without the addition of a substitute or a therapeutic agent.

Osteopontine (OPN): Bone matrix protein used as an immunohistochemical marker in the study to identify mature lamellar bone formation and graft integration by the host.

nHA (Nano-hydroxyapatite): Low-crystallinity hydroxyapatite particles periodically arranged between collagen molecules. This specific configuration provides the MC material with tissue-guiding properties similar to human bone.

Alizarin Red S: Dye used during in vitro tests to quantify the calcium mineralization of bone marrow mesenchymal stem cells (BMSCs) cultured on different supports.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility regarding the use of this information. This document is not intended for patients or the general public.